How Investors Can Cash In on the Boom in the Psychedelic Field

The psychedelic sector has seen major growth in the past few years as consumer interest in psychedelic drugs as alternative medicines has increased. As research into psychedelics picks up steam and lawmakers discuss legalizing the substances, industry experts project that the psychedelics industry will experience significant growth over the next decade.

Last year was a pretty good year for the nascent sector, and a new report indicates the industry could reach even greater highs in 2022. For investors who are looking to diversify their portfolio and invest in an emerging industry, psychedelics present an attractive opportunity.

According to the Defiance ETFs report, the psychedelic industry’s growth has been pushed by positive legislation changes, clinical trials that have reported positive results regarding psychedelics and their effects, an increase in demand for psychedelics and public acceptance of psychedelics as alternative medications.

Most predictions for the future of the young psychedelics sector are positive; DataBridge predicted that between 2021 and 2026, the American psychedelic market will grow at a compound annual growth rate (“CAGR”) of 11.5% to reach a $6.4 billion valuation by 2028.

Similarly, data from Research and Markets predicted that the psychedelics market in the U.S. will grow at a CAGR of 14.5% from $3.2 billion in 2021 to a valuation of $6.3 billion in 2026.

The report from Defiance ETFs notes that it is clear that most analysts expect dramatic growth even if they may not agree on the exact size of that growth. This is especially true as psychedelics gain increasing levels of popularity due to their supposed mental health benefits. Defiance ETFs’ CIO and cofounder Sylvia Jablonski noted that more than 2 billion people have untreated mental health disorders, and the number is rising.

At least 30% of them still haven’t found a conventional treatment or cure that works and have mostly given up, she said. This is despite the billions of dollars invested in fighting mental health problems. But thanks to clinical research from research groups and academic institutions, we now have empirical evidence that psychedelic-based medicines have the potential to revolutionize mental health care.

Forward-thinking investors could snatch up attractive psychedelics stock while the sector is still in the beginning stages, she said. Jablonski mentioned companies such as Mind Medicine, which focuses on LSD and ibogaine, and has a $1 billion market valuation. Another company to consider is Compass Pathways, which is currently running the largest psilocybin clinical trial in history. Other firms, including Delic Holdings Corp. (CSE: DELC) (OTC: DELCF), are also growing their physical footprint across different provinces and jurisdictions.

NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.